Lenvatinib for the treatment of HCC: A single institute experience.

e15611Background: Lenvatinib, a multiple kinase inhibitor, is an emerging for the treatment of advanced HCC. In REFLECT study, lenvatinib demonstrated higher ORR and longer PFS than sorafenib as th...